The first deal of the joint investment fund established by Japan Bank for International Cooperation (JBIC) and Russian Direct Investment Fund (RDIF) will be investment in R-Pharm, a Russian pharmaceutical company.
This was announced by Kirill Dmitriev, the Head of RDIF, in an interview with TASS news agency at the Eastern Economic Forum.
“Today, I am ready to announce our first deal, the investment in R-Pharm of Mr. (Alexey) Repik. This is not a casual investment, we believe that this is a good company,” said Mr. Dmitriev.
Alexey Repik is the principal owner of R-Pharm. Earlier, he said that Mitsui, a Japanese corporation, will buy the first 10% of R-Pharm for about $200 million. It is expected that the deal will be closed in September 2017.
As part of the deal, Mitsui has an option to increase its stake to 20% on the same terms as for the first 10% stake. It is assumed that Mitsui will increase its share along with the engagement of major public financial and industrial investors.
“For the fund, this involves dozens of million dollars,” said Mr. Dmitriev in response to the question on the amount that the new Russian-Japanese fund plans to invest in R-Pharm.